先聲藥業(02096.HK)香港發售獲約589.47倍認購 上限定價13.70港元/股
格隆匯 10 月 23日丨先聲藥業(02096.HK)發佈公告,公司擬全球發售約2.61億股股份,其中香港發售股份約1.30億股,國際發售股份約1.30億股,另有15%超額配股權;發售價已釐定為每股發售股份13.70港元,每手買賣單位1000股;摩根士丹利及中金公司為聯合保薦人,預期股份將於2020年10月27日於聯交所主板掛牌上市。
香港公開發售項下初步提呈發售的香港發售股份已獲非常大幅超額認購。已接獲合共362,035份有效申請,認購合共約153.60億股香港發售股份,相當於香港公開發售項下初步可供認購股份總數約589.47倍。國際發售項下初步提呈發售的發售股份獲超額認購約23倍。
基於發售價每股發售股份13.70港元,根據基石投資協議,基石投資者已認購合共約1.07億股發售股份,合共佔緊隨全球發售完成後本公司已發行股本約4.12%;及全球發售項下發售股份數目約41.25%,在每種情況下均假設超額配股權未獲行使。
按發售價每股發售股份13.70港元計算,並假設超額配股權未獲行使,公司自全球發售收到的所得款項淨額估計約為33.924億港元。公司擬將全球發售所得款項約60%分配予公司在戰略重點治療領域中選定的在研產品的持續研發;約10%將分配予加強公司的銷售及營銷能力;約10%將分配予公司於未來幾年投資醫藥或生物技術領域的公司,以拓寬公司的產品組合;約10%將分配予償還若干未償還銀行貸款;及約10%將用作營運資金及其他一般企業用途。倘超額配股權獲悉數行使,公司將就於超額配股權獲行使時將予出售及轉讓的3908.5萬股額外發售股份收取額外所得款項淨額約5.167億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.